{"id":57746,"date":"2024-07-30T00:04:34","date_gmt":"2024-07-30T00:04:34","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/07\/30\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/"},"modified":"2024-07-30T00:04:34","modified_gmt":"2024-07-30T00:04:34","slug":"bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/","title":{"rendered":"Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis"},"content":{"rendered":"<div>\n<p><span class=\"legendSpanClass\">SEONGNAM, <span class=\"xn-location\">South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 30, 2024<\/span><\/span> \/PRNewswire\/ &#8212; Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in <span class=\"xn-location\">South Korea<\/span> developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-877, a novel autotoxin (ATX) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF).<\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05483907\" target=\"_blank\" rel=\"nofollow noopener\">The Phase 2, multi-center, randomized, double-blind, placebo-controlled study (NCT05483907)<\/a>\u00a0aims to evaluate the efficacy, safety, and tolerability of BBT-877 in patients with IPF, with or without anti-fibrotic (AF) approved background therapies (pirfenidone or nintedanib). The primary objective is the evaluation of the efficacy of BBT-877 in IPF patients by measuring the reduction in forced vital capacity (FVC) in patients treated with BBT-877 compared to those treated with a placebo at week 24 of treatment. Secondary objectives of the study include the evaluation of drug safety, pharmacokinetics (PK), diffusing capacity of lung for carbon monoxide (DLCO), and functional exercise capacity in all patients.<\/p>\n<p>A total of 120 patient participants were enrolled from approximately 50 clinical trial sites located in the U.S., <span class=\"xn-location\">South Korea<\/span>, <span class=\"xn-location\">Australia<\/span>, <span class=\"xn-location\">Poland<\/span>, and <span class=\"xn-location\">Israel<\/span>, representing diversity of ethnicity and race. Patients were randomized to either the experimental drug arm or the placebo arm, following a 200mg, twice daily (BID) regimen of BBT-877 or a placebo.<\/p>\n<p><span class=\"xn-person\">James Lee<\/span>, founder and CEO of Bridge Biotherapeutics, said: &#8220;The completion of enrollment in the phase 2a clinical study of BBT-877 marks an important milestone in our efforts to develop innovative treatments for patients suffering from IPF. Closely looking for business alliance opportunities in the global pharmaceutical industry, we will remain dedicated to advancing this novel drug candidate, which we believe has the potential to make clinically meaningful outcomes in IPF patients.&#8221;<\/p>\n<p>The Company expects topline data from this study to be announced in the first half of 2025. In parallel with advancing the study, the company pursues a global partnership to prepare for the next phase of the study to further validate the efficacy and safety of BBT-877 in a larger number of patients around the world.<\/p>\n<p>BBT-877, an experimental Autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by up to 90 percent in the first-in-human study. LPA is known to bind\u00a0to cell receptors and induce various physiological activities, such as neovascularization, sclerosis, tumorigenesis, and tumor metastasis, leading to the development of various fibrotic diseases, including IPF.\u00a0The National Institutes of Health (NIH) in the U.S. estimates that more than 30,000 new cases of IPF are diagnosed in the U.S. alone each year, and as many as 3 million patients are affected worldwide.<\/p>\n<p><b>About Bridge Biotherapeutics, Inc.<\/b><\/p>\n<p>Bridge Biotherapeutics Inc., based in the Republic of Korea and the U.S., is a publicly traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs, including fibrotic diseases and cancers. The company is developing BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-207, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with EGFR C797S mutations. Learn more at <a href=\"https:\/\/www.bridgebiorx.com\/en\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.bridgebiorx.com\/en\/<\/a>.<\/p>\n<p><b>About BBT-877<\/b><\/p>\n<p>BBT-877 is an orally administered autotaxin enzyme inhibitor which is under development as a treatment for idiopathic pulmonary fibrosis (IPF). During the Phase 1 Clinical Study, the experimental autotaxin inhibitor demonstrated lysophosphatidic acid (LPA) inhibition of up to 90 percent in multiple-ascending dose cohorts. The topline data of the Phase 2a Clinical Study are expected to be announced in the first half of 2025.<\/p>\n<p><b>About Autotaxin<\/b><\/p>\n<p>Autotaxin (ATX), a protein of approximately 900 amino acids discovered in the early 1990s, is an important enzyme for generating the lipid-signaling molecule, lysophosphatidic acid (LPA). Autotaxin&#8217;s lysophospholipase D activity converts lysophosphatidylcholine (LPC) into LPA, which engages in signaling via LPA receptors. LPA signaling results in cell proliferation, migration, secretion of cytokines and chemokines, and reduction of cell apoptosis. Ultimately, autotaxin has a pathogenic role in processes of inflammation and fibrosis, making it an attractive drug target.<\/p>\n<p><b>About idiopathic pulmonary fibrosis (IPF)<\/b><\/p>\n<p>IPF is a rare, debilitating, and fatal lung disease that affects approximately 3 million people worldwide. The progression of IPF is variable and unpredictable. Over time, the lung function of an IPF patient gradually and irreversibly declines.<\/p>\n<p>\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEONGNAM, South Korea, July 30, 2024 \/PRNewswire\/ &#8212; Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-877, a novel autotoxin (ATX) inhibitor for the treatment of idiopathic pulmonary fibrosis [&#8230;]\n","protected":false},"author":1,"featured_media":79226,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-57746","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis\" \/>\n<meta property=\"og:description\" content=\"SEONGNAM, South Korea, July 30, 2024 \/PRNewswire\/ &#8212; Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea dev\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-30T00:04:34+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis\",\"datePublished\":\"2024-07-30T00:04:34+00:00\",\"dateModified\":\"2024-07-30T00:04:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/\"},\"wordCount\":725,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/\",\"name\":\"Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-07-30T00:04:34+00:00\",\"dateModified\":\"2024-07-30T00:04:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/","og_locale":"en_US","og_type":"article","og_title":"Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis","og_description":"SEONGNAM, South Korea, July 30, 2024 \/PRNewswire\/ &#8212; Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea dev","og_url":"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-07-30T00:04:34+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis","datePublished":"2024-07-30T00:04:34+00:00","dateModified":"2024-07-30T00:04:34+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/"},"wordCount":725,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/","url":"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/","name":"Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-07-30T00:04:34+00:00","dateModified":"2024-07-30T00:04:34+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/bridge-biotherapeutics-announces-completion-of-enrollment-in-the-phase-2a-clinical-study-of-bbt-877-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=57746"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57746\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/79226"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=57746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=57746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=57746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}